Content Model

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) 1. 73.80%. Evaluation of Ertugliflozin EffIcacy and Safety CardioVascular Outcomes (VERTIS-CV) 2. 76.30%. Canagliflozin Cardiovascular Assessment Study (CANVAS) 3. 77.20%. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE–TIMI 58) 4. NA ................
................